News and Announcements
Anteo Diagnostics Ltd Acquires DIAsource ImmunoAssays SA & Other Highlights
- Published July 06, 2016 11:19AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Revenues of €14.171M in CY15 growing at greater than 10% per annum
DIAsource provides a strong platform
Other highlights from the past 12 months include:
- Filed two new patents in battery (energy) space
- Appointed new distributors, including Sigma Aldrich
- Successful trip to Tokyo Battery Expo yielded strong interest with global battery companies
- Appointed Dr Jef Vangenechten Global CEO and Mr Rolf Sickman to the Board
- Collaborating with Cook Medical on medical devices
- Awarded funding for the development of a new rapid blood test for heart attacks in partnership with Atomo Diagnostics
ABOUT ANTEO DIAGNOSTICS
Anteo Diagnostics (ASX: ADO) is a global medical technology company, developing and commercialising products for sale into the lifesciences, in-vitro diagnostics, point of care, medical devices and bioseparations markets.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
